Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Zile, MR; Jhund, PS; Baicu, CF; Claggett, BL; Pieske, B; Voors, AA; Prescott, MF; Shi, V; Lefkowitz, M; McMurray, JJ; Solomon, SD; Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators.
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Circ Heart Fail. 2016; 9(1):
Doi: 10.1161/CIRCHEARTFAILURE.115.002551
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Pieske Burkert Mathias
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Heart failure with preserved ejection fraction is a clinical syndrome that has been associated with changes in the extracellular matrix. The purpose of this study was to determine whether profibrotic biomarkers accurately reflect the presence and severity of disease and underlying pathophysiology and modify response to therapy in patients with heart failure with preserved ejection fraction. Four biomarkers, soluble form of ST2 (an interleukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III N-terminal propeptide were measured in the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) trial at baseline, 12 and 36 weeks after randomization to valsartan or LCZ696. We examined the relationship between baseline biomarkers, demographic and echocardiographic characteristics, change in primary (change in N-terminal pro B-type natriuretic peptide) and secondary (change in left atrial volume) end points. The median (interquartile range) value for soluble form of ST2 (33 [24.6-48.1] ng/mL) and galectin 3 (17.8 [14.1-22.8] ng/mL) were higher, and for matrix metalloproteinase-2 (188 [155.5-230.6] ng/mL) lower, than in previously published referent controls; collagen III N-terminal propeptide (5.6 [4.3-6.9] ng/mL) was similar to referent control values. All 4 biomarkers correlated with severity of disease as indicated by N-terminal pro B-type natriuretic peptide, E/E', and left atrial volume. Baseline biomarkers did not modify the response to LCZ696 for lowering N-terminal pro B-type natriuretic peptide; however, left atrial volume reduction varied by baseline level of soluble form of ST2 and galectin 3; patients with values less than the observed median (<33 ng/mL soluble form of ST2 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those above median did not. Although LCZ696 reduced N-terminal pro B-type natriuretic peptide, levels of the other 4 biomarkers were not affected over time. In patients with heart failure with preserved ejection fraction, biomarkers that reflect collagen homeostasis correlated with the presence and severity of disease and underlying pathophysiology, and may modify the structural response to treatment. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00887588. © 2016 American Heart Association, Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Aminobutyrates - therapeutic use
- Angiotensin II Type 1 Receptor Blockers - therapeutic use
- Angiotensin Receptor Antagonists - therapeutic use
- Biomarkers - blood
- Double-Blind Method -
- Drug Combinations -
- Female -
- Fibrosis -
- Galectin 3 - blood
- Heart Failure - blood
- Heart Failure - diagnosis
- Heart Failure - drug therapy
- Humans -
- Interleukin-1 Receptor-Like 1 Protein -
- Male -
- Matrix Metalloproteinase 2 - blood
- Middle Aged -
- Myocardium - metabolism
- Myocardium - pathology
- Peptide Fragments - blood
- Procollagen - blood
- Prospective Studies -
- Receptors, Cell Surface - blood
- Severity of Illness Index -
- Stroke Volume -
- Tetrazoles - therapeutic use
- Treatment Outcome -
- Valsartan - therapeutic use
- Ventricular Function, Left -
- Find related publications in this database (Keywords)
- biomarkers
- extracellular matrix
- heart failure
- homeostasis
- pathophysiology